SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series.
Marko ŠkrtićDavid Z I CherneyVikas S SridharChristopher T M ChanAbhijat KitchluPublished in: Canadian journal of kidney health and disease (2021)
SGLT2 inhibition is becoming a standard component of nephrology care to reduce kidney function decline, cardiovascular risk, and mortality. To our knowledge, our report is the first to provide longitudinal data on SGLT2 inhibitor usage in patients with T2D and solitary kidneys post-nephrectomy. Larger prospective studies are needed to determine the efficacy and safety of SGLT2 inhibition strategies for kidney protection in patients post-nephrectomy.
Keyphrases
- robot assisted
- healthcare
- editorial comment
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- cardiovascular events
- cardiovascular disease
- cross sectional
- electronic health record
- quality improvement
- big data
- coronary artery disease
- patient reported
- pain management
- chronic pain
- artificial intelligence
- affordable care act
- health insurance
- case control